Technology-Based Care for Diabetic Ketoacidosis
(DKA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The study team proposes that use of a novel multi-disciplinary approach with continuous glucose monitoring technology can significantly improve glycemic control and reduce readmissions among those with type 1 diabetes mellitus (T1DM) admitted for Diabetic ketoacidosis (DKA). This will also help promote a pathway for care of these patients after admission utilizing resources which are available within the Endocrinology, Diabetes and Metabolism department at the Cleveland Clinic.
Do I need to stop my current medications for this trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
Is continuous glucose monitoring safe for humans?
Continuous glucose monitoring (CGM) systems, including real-time (rtCGM) and intermittently scanned (isCGM), have been used safely in adults and children with type 1 diabetes to help manage blood sugar levels. These systems are generally considered safe, but their use in specific conditions like diabetic ketoacidosis (DKA) in children has not been well studied.12345
How does Continuous Glucose Monitoring (CGM) differ from other treatments for diabetic ketoacidosis?
Continuous Glucose Monitoring (CGM) is unique because it provides real-time or intermittently scanned glucose data, allowing for continuous tracking of blood sugar levels, which can help prevent diabetic ketoacidosis (DKA) by alerting users to dangerous glucose trends. Unlike traditional methods that require manual blood sugar checks, CGM offers a more proactive approach to managing diabetes, although its accuracy can be affected during severe DKA episodes.13678
What data supports the effectiveness of the treatment Technology-Based Care for Diabetic Ketoacidosis?
Who Is on the Research Team?
Zhou Keren, MD
Principal Investigator
The Cleveland Clinic
Are You a Good Fit for This Trial?
This trial is for individuals with Type 1 Diabetes who have been admitted for Diabetic Ketoacidosis (DKA). It's designed to test if a new care approach using technology can improve blood sugar control and reduce hospital readmissions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive continuous glucose monitoring (CGM) technology to improve glycemic control
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Continuous Glucose Monitoring (CGM)
Continuous Glucose Monitoring (CGM) is already approved in United States, European Union, Canada for the following indications:
- Type 1 diabetes
- Type 2 diabetes
- Gestational diabetes
- Hypoglycemia unawareness
- High glycemic variability
- Type 1 diabetes
- Type 2 diabetes
- Gestational diabetes
- Hypoglycemia unawareness
- High glycemic variability
- Type 1 diabetes
- Type 2 diabetes
- Gestational diabetes
- Hypoglycemia unawareness
- High glycemic variability
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Cleveland Clinic
Lead Sponsor